Literature DB >> 11586057

Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis.

M Santos Lacomba1, C Marcos Martín, J M Gallardo Galera, M A Gómez Vidal, E Collantes Estévez, R Ramírez Chamond, M Omar.   

Abstract

OBJECTIVE: To study the local and systemic behavior of the tumor necrosis factor-alpha (TNF-alpha) in patients with active uveitis.
METHODS: TNF-alpha levels were measured in aqueous humor and peripheral blood samples using an enzyme-linked immunosorbent assay from 23 patients with uveitis and 16 control patients who had been operated on for uncomplicated cataracts.
RESULTS: Aqueous humor and sera of patients with uveitis showed higher levels of TNF-alpha than those of controls (p < 0.001). A comparison of cytokine levels between aqueous humor and sera showed significantly higher levels of TNF-alpha in serum than aqueous humor (p < 0.001). Correlation studies using the regression test for successive steps showed that serum TNF-alpha levels correlated with recurrent uveitis (r = 0.4150; p = 0.0489).
CONCLUSIONS: TNF-alpha is a cytokine that participates actively in the pathogenesis of clinical uveitis. Our data emphasize the greater systemic than local participation of TNF-alpha. Finally, an elevated serum TNF-alpha seems to be associated with a recurrent pattern of uveitis. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11586057     DOI: 10.1159/000055677

Source DB:  PubMed          Journal:  Ophthalmic Res        ISSN: 0030-3747            Impact factor:   2.892


  79 in total

1.  Systemic CD4(+) T cell phenotype and activation status in intermediate uveitis.

Authors:  C C Murphy; L Duncan; J V Forrester; A D Dick
Journal:  Br J Ophthalmol       Date:  2004-03       Impact factor: 4.638

2.  Prevention of endotoxin-induced uveitis in rats by plant sterol guggulsterone.

Authors:  Nilesh M Kalariya; Mohammad Shoeb; Aramati B M Reddy; Min Zhang; Frederik J G M van Kuijk; Kota V Ramana
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-04-30       Impact factor: 4.799

3.  [Biologics in ophthalmology].

Authors:  U Pleyer
Journal:  Ophthalmologe       Date:  2011-01       Impact factor: 1.059

Review 4.  [Anti-TNF-α treatment for uveitis. Analysis of the current situation].

Authors:  U Pleyer; F Mackensen; S Winterhalter; N Stübiger
Journal:  Ophthalmologe       Date:  2011-01       Impact factor: 1.059

Review 5.  Management of sight-threatening uveitis: new therapeutic options.

Authors:  Matthias D Becker; Justine R Smith; Regina Max; Christoph Fiehn
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 6.  Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology.

Authors:  Piergiorgio Neri; Manuela Zucchi; Pia Allegri; Marta Lettieri; Cesare Mariotti; Alfonso Giovannini
Journal:  Int Ophthalmol       Date:  2011-02-02       Impact factor: 2.031

7.  Preventive effect of tumor necrosis factor inhibitors versus nonsteroidal anti-inflammatory drugs on uveitis in patients with ankylosing spondylitis.

Authors:  Min Jung Kim; Eunyoung Emily Lee; Eun Young Lee; Yeong Wook Song; Hyeong Gon Yu; Yunhee Choi; Eun Bong Lee
Journal:  Clin Rheumatol       Date:  2018-08-04       Impact factor: 2.980

8.  Evaluation of potential retinal toxicity of adalimumab (Humira).

Authors:  Miltiadis Tsilimbaris; Vasilios F Diakonis; Irini Naoumidi; Spyridon Charisis; Iraklis Kritikos; George Chatzithanasis; Thekla Papadaki; Sotiris Plainis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-03-19       Impact factor: 3.117

9.  Intravitreal administration of the anti-TNF monoclonal antibody infliximab in the rabbit.

Authors:  Panagiotis G Theodossiadis; Vasilios S Liarakos; Petros P Sfikakis; Alexander Charonis; Georgios Agrogiannis; Nikolaos Kavantzas; Ioannis A Vergados
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-04       Impact factor: 3.117

10.  Inflammatory molecules in aqueous humour and on ocular surface and glaucoma surgery outcome.

Authors:  Barbara Cvenkel; Andreja Natasa Kopitar; Alojz Ihan
Journal:  Mediators Inflamm       Date:  2010-05-05       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.